Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service sinus surgery & balloon dilation cases in Arkansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (231 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 12 | 961 | 29% |
| 2020 | 5 | 656 | 32% |
| 2021 | 2 | 550 |
Balloon sinuplasty and functional endoscopic sinus surgery. Professional codes (what the surgeon bills): CPT 31295, 31296, 31297, 31298, 31255, 31267, 31276, 31287, 31288, 31237.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Arkansas; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
Sinus surgery & balloon dilation in every state, and its device makers · Every procedure market in Arkansas · Every state · Compare with Texas
| 2024 |
| 620 |
| 49% |
| 2025 est. | ≈ 850 | – |
| 2026 est. | ≈ 860 | – |
| 37% |
| 2022 | 5 | 580 | 40% |
| 2023 | 3 | 452 | 46% |
| 2024 | 7 | 620 | 49% |
| 2025 from claims | – | 851 688–999 | 50% |
| 2026 forecast | – | 859 673–1,079 | 51% |
| 2027 forecast | – | 867 643–1,146 | 51% |
| 2028 forecast | – | 875 619–1,208 | 52% |
| 2029 forecast | – | 883 600–1,266 | 53% |
| 2030 forecast | – | 890 583–1,321 | 53% |
In 2025, 31% hospital outpatient, 69% office. The share outside the hospital has moved −18 pts since 2019.
| 0%/yr |
| 6.6 |
| 92% |
| 19,700 in 2030+5.2%/yr |
| Georgia | 44 | 4,459−4%/yr | −4%/yr | 5.2 | 88% | 4,620 in 2030+0.6%/yr |
| North Carolina | 39 | 3,683−8.4%/yr | −8.4%/yr | 3.8 | 87% | 4,040 in 2030+1.6%/yr |
| Tennessee | 40 | 3,324+0.1%/yr | +0.1%/yr | 4.8 | 84% | 4,300 in 2030+4.4%/yr |
| South Carolina | 33 | 3,194−0.9%/yr | −0.9%/yr | 4.7 | 86% | 4,830 in 2030+7.1%/yr |
| Alabama | 30 | 3,147−2.3%/yr | −2.3%/yr | 7.3 | 85% | 3,630 in 2030+2.4%/yr |
| Virginia | 23 | 2,887−4.8%/yr | −4.8%/yr | 2.8 | 80% | 2,650 in 2030−1.4%/yr |
| Louisiana | 31 | 2,414−5.1%/yr | −5.1%/yr | 6.0 | 73% | 2,260 in 2030−1.1%/yr |
| Maryland | 29 | 2,344−4.8%/yr | −4.8%/yr | 2.7 | 95% | 1,970 in 2030−2.8%/yr |
| Oklahoma | 17 | 2,185+7.6%/yr | +7.6%/yr | 4.5 | 69% | 3,570 in 2030+8.5%/yr |
| Mississippi | 20 | 1,659−6.5%/yr | −6.5%/yr | 4.5 | 91% | 1,580 in 2030−0.9%/yr |
| Kentucky | 10 | 1,177−7.5%/yr | −7.5%/yr | 2.6 | 88% | 1,340 in 2030+2.2%/yr |
| Delaware | 6 | 435−5.7%/yr | −5.7%/yr | 2.6 | 88% | 480 in 2030+1.7%/yr |
| District of Columbia | 3 | 234−13%/yr | −13%/yr | 3.8 | 98% | 250 in 2030+0.9%/yr |
| West Virginia | 1 | 228−14%/yr | −14%/yr | 1.1 | 55% | 150 in 2030−6.5%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Integra LifeSciences leads with 53% of company spending on these surgeons in 2025, +19 pts on 2024.
In 2025, 6 companies reported engagement with Arkansas’s surgeons worth $758 in consulting, speaking, meals and travel tied to these products, about $108 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 3 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.